PGC-1α Suppresses the Activation of TGF-β/Smad Signaling via Targeting TGFβRI Downregulation by let-7b/c Upregulation.
Hoon-In ChoiJung Sun ParkDong-Hyun KimChang Seong KimEun Hui BaeSeong Kwon MaYong-Soo KimPublished in: International journal of molecular sciences (2019)
TGF-β/Smad signaling is a major pathway in progressive fibrotic processes, and further studies on the molecular mechanisms of TGF-β/Smad signaling are still needed for their therapeutic targeting. Recently, peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) was shown to improve renal fibrosis, making it an attractive target for chronic kidney diseases (CKDs). Here, we show the mechanism by which PGC-1α regulates the TGF-β/Smad signaling pathway using HK-2 cell lines stably overexpressing empty vector (mock cells) or human PGC1α (PGC1α cells). Stable PGC-1α overexpression negatively regulated the expression of TGF-β-induced epithelial-mesenchymal transition (EMT) markers (fibronectin, E-cadherin, vimentin, and α-SMA) and EMT-related transcription factors (Snail and Slug) compared to mock cells, inhibiting fibrotic progression. Interestingly, among molecules upstream of Smad2/3 activation, the gene expression of only TGFβRI, but not TGFβRII, was downregulated in PGC-1α cells. In addition, the downregulation of TGFβRI by PGC-1α was associated with the upregulation of let-7b/c, miRNA for which the 3' untranslated region (UTR) of TGFβRI contains a binding site. In conclusion, PGC-1α suppresses TGF-β/Smad signaling activation via targeting TGFβRI downregulation by let-7b/c upregulation.
Keyphrases
- transforming growth factor
- epithelial mesenchymal transition
- signaling pathway
- induced apoptosis
- skeletal muscle
- pi k akt
- cell cycle arrest
- gene expression
- cell proliferation
- transcription factor
- poor prognosis
- systemic sclerosis
- oxidative stress
- cell death
- drug delivery
- multiple sclerosis
- idiopathic pulmonary fibrosis
- cancer therapy
- diabetic rats